Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

04/20/2012 | 08:16pm US/Eastern
Recommend:
0

Biostar Pharmaceuticals, Inc. Regains Compliance with NASDAQ's Minimum Bid Price Requirement

XIANYANG, China, April 20, 2012/PRNewswire-Asia/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in Chinafor a variety of diseases and conditions, today announced that it has received written notification from the Nasdaq Listing Qualifications department that it has regained compliance with the minimum bid price requirement of $1.00per share for continued listing of its common stock on The NASDAQ Global Market set forth in Nasdaq Listing Rule 5450(a)(1), as its common shares achieved a closing bid price of $1.00or more for 10 consecutive business days prior to the compliance deadline of April 23, 2012and this matter is now closed.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to maintain its ongoing compliance with the Nasdaq continued listing requirements, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, its ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, its ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2011, and other subsequent filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:




BioStar Pharmaceuticals, Inc. 

The Equity Group, Inc.

Zack Pan, CFO 

Lena Cati

Tel: 405-996-8829 

Tel: 212 836-9611

Email: zpan@aoxing-group.com

Email: lcati@equityny.com

SOURCE Biostar Pharmaceuticals, Inc.

distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago BAYERISCHE MOTOREN WERKE : The new BMW 2 Series Active Tourer
<1m ago HSBC : launches the 2014 Yes 4 Students campaign
<1m ago RE/MAX : Malta launch charity foundation during 10th anniversary celebration
<1m ago DAIMLER : Double win for Mercedes-Benz at Auto Express Awards
<1m ago KATAHDN BKSHS : Hold for Friday (7/25): Fendler's tale still resonates, 75 years later
<1m ago ALCATEL LUCENT : SFR to compensate users following network outage
<1m ago TIM PARTICIPACOES : Telecom Italia CEO says TIM Brasil will participate in 4G 700MHz auction
<1m ago RAIFFEISEN BANK : Malta Bank sold to Kronospan, renamed ECCM Bank plc
<1m ago MALTA AIRPORT : Attempt to smuggle 400 bird skins foiled at airport
<1m ago MALTA AIRPORT : Mgarr man held for questioning over smuggling 411 bird skins
Latest news
Advertisement
Hot News 
EUROPLASMA : Annual Shareholders Meeting of 1st September, 2014
DOTDIGITAL : Non-Executive Chairman's Trust Sells Shares (DIRECTOR DEALINGS)
GRENKELEASING : Consolidated Group net profit rises 40% in the first half of 2014 and is at the upper end of our full-year expectations (DGAP News)
MAGELLAN HEALTH SERVICES : Reports Second Quarter 2014 Financial Results
NEWPARK RESOURCES : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
Most Read News
1d ago MASTERCARD : Visa cuts revenue forecast as cross-border transactions slow
1d ago STARBUCKS : sales in Americas region up slightly more than expected
1d ago MOODY : assigns A1 underlying and Aa3 enhanced ratings to Catskill CSD NY's $5.9M GO Bonds
1d ago COCA COLA : Governor denies switching to Fanta to boycott Coca-Cola
7h ago In China meat scandal, McDonald's Japan switches to Thai chicken, no nuggets in Hong Kong
Most recommended articles
1m agoDJEUROPE MARKETS : Euro, German Stocks Fall After Downbeat Sentiment Data
7m ago Alitalia investors approve cash call to buy time for Etihad deal
51m ago EUR/USD Risks Further Losses Ahead of ECB Meeting; CPI in Focus
1h agoDJLONDON MARKETS : RBS Shares Leap In London, But BSkyB Drops
1h agoDJUK Data to Show Manufacturing Strength Steady
Dynamic quotes  
ON
| OFF